How does CAR T cell therapy work?

Science and life
122 followers
Chimeric Antigen Receptor, or CAR-T cell therapy, is a type of immunotherapy under
investigation for the treatment of myeloma. CAR-T uses genetically programmed T-cells
from your own immune system to kill cancerous myeloma cells.
Treatment with CAR-T happens in several steps. First, you will be evaluated to determine if
CAR-T is an appropriate treatment option. Things such as age, previous lines of therapy,
and general fitness will be considered. If you and your doctor agree to proceed
with CAR-T treatment, the next step will be to collect blood by placing a needle in your arm.
Your white blood cells are then collected through a process called leukapheresis.
The white blood cells are then sent to a laboratory where specific types of immune
cells, known as T-cells, are extracted. Then, the T-cells are genetically programmed,
using a virus or other methods, to express the Chimeric Antigen Receptor, or CAR protein,
on the surface of the T-cells. The CAR-T cells are then grown in the laboratory in preparation
for reinfusion into your body. In the meantime, you will be given chemotherapy to help your body
accept the genetically programmed T-cells, now called CAR-T cells.
Once the CAR-T cell processing is complete, you will be admitted to the hospital.
The CAR-T cells are infused back into your body through a needle inserted in your arm.
The addition of the CAR protein on the surface of the T-cells
helps them to find and destroy the myeloma cells in your body.
CAR-T can produce many side effects, and it is important for doctors to closely monitor
your symptoms. Side effects can be severe, and most patients may have to stay in the hospital
for at least two weeks, or even be admitted to the intensive care unit while being treated with
CAR-T. While each person may respond to CAR-T differently, the common side effects of this
treatment are low blood cell counts, such as red blood cells and white blood cells,
cytokine release syndrome, which is a flu-like syndrome that can be mild or severe,
and neurotoxicity, which may lead to symptoms such as confusion.
Side effects of receiving CAR-T therapy can be treated by using drugs such as teclizumab.
Also, some CAR-T treatments may be programmed with an off switch that can be utilized in
situations where patients experience serious side effects. After you leave the hospital,
you will continue to be closely monitored by your health care team for any further side effects.
Early results investigating CAR-T show that it is a promising therapy for the treatment of myeloma.
However, further research is still ongoing.
For more information on myeloma and myeloma treatments, please check out the MPE website.
